HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Business Round-Up: ColdZyme Heading To MENA, Kerry Expands Probiotics Offering, Galenica Launches Vita-Merfen

Executive Summary

Latest EU company news: Enymatica strikes deal to take its ColdZyme common cold product into MENA; Ireland's Kerry snaps up Canadian probiotics specialist Bio-K Plus; and Switerland's Galenica relaunches Vita-Merfen after a five-year absence. 

You may also be interested in...



EU Probiotics News: Strong Year For Probi, BioGaia Struggles, Kerry Targets Biosearch Deal

Latest European Probiotics News: Probi and BioGaia post earnings, with differing results, while Kerry seeks to expand with Spain's Biosearch.

RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.

RB Shows Scholl The Door, While Welcoming In Biofreeze

Reckitt is refocusing its consumer health portfolio by offloading the troubled Scholl brand and acquiring fast-growing US topical analgesic Biofreeze.

Topics

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel